Skip to main content
Top
Published in: Annals of Surgical Oncology 9/2015

Open Access 01-09-2015 | Bone and Soft Tissue Sarcomas

Time Trends in the Incidence and Treatment of Extra-Abdominal and Abdominal Aggressive Fibromatosis: A Population-Based Study

Authors: Danique L. M. van Broekhoven, MD, Dirk J. Grünhagen, MD, PhD, Michael A. den Bakker, MD, PhD, Thijs van Dalen, MD, PhD, Cornelis Verhoef, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2015

Login to get access

Abstract

Background

Aggressive fibromatosis (AF) is a locally infiltrating soft-tissue tumor. In a population-based study in the Netherlands, we evaluated time trends for the incidence and treatment of AF.

Methods

In PALGA: Dutch Pathology Registry, all patients diagnosed between 1993 and 2013 as having extra-abdominal or abdominal wall aggressive fibromatosis were identified and available pathology data of the patients were evaluated. Epidemiological and treatment-related factors were analyzed with χ 2and regression analysis.

Results

During the study period, 1134 patients were identified. The incidence increased from 2.10 to 5.36 per million people per year. Median age at the time of diagnosis increased annually by B 0.285 (P = 0.001). Female gender prevailed and increased over time [annual odds ratio (OR) 1.022; P = 0.058]. All anatomic localizations, but in particular truncal tumors, became more frequent. During the study period diagnostic histological biopsies were performed more often (annual OR 1.096; P < 0.001). The proportion of patients who underwent surgical treatment decreased (annual OR 0.928; P < 0.001). When resection was preceded by biopsy, 49.8 % of the patients had R0-resection versus 30.7 % in patients without biopsy (P < 0.001).

Conclusions

In this population-based study, an increasing incidence of extra-abdominal and abdominal-wall aggressive fibromatosis was observed. The workup of patients improved and a trend towards a nonsurgical treatment policy was observed.
Literature
1.
go back to reference Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997;151(2):329–34.PubMedCentralPubMed Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997;151(2):329–34.PubMedCentralPubMed
2.
go back to reference Tejpar S, Michils G, Denys H, et al. Analysis of Wnt/Beta catenin signalling in desmoid tumors. Acta Gastroenterol Belg. 2005;68(1):5–9.PubMed Tejpar S, Michils G, Denys H, et al. Analysis of Wnt/Beta catenin signalling in desmoid tumors. Acta Gastroenterol Belg. 2005;68(1):5–9.PubMed
3.
go back to reference Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and beta-catenin in the aetiology of aggressive fibromatoses (desmoid tumors). Eur J Surg Oncol. 2009;35:3–10.PubMedCrossRef Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and beta-catenin in the aetiology of aggressive fibromatoses (desmoid tumors). Eur J Surg Oncol. 2009;35:3–10.PubMedCrossRef
4.
go back to reference Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F, eds. Tumours of soft tissue and bone: pathology and genetics. World Health Organization classification of tumours, 4th edn. Lyon: IARC Press; 2013. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F, eds. Tumours of soft tissue and bone: pathology and genetics. World Health Organization classification of tumours, 4th edn. Lyon: IARC Press; 2013.
5.
go back to reference Devata S, Chugh R. Desmoid tumors: a comprehensive review of the evolving biology, unpredictable behavior, and myriad of management options. Hematol Oncol Chil North Am. 2013;27:989–1005.CrossRef Devata S, Chugh R. Desmoid tumors: a comprehensive review of the evolving biology, unpredictable behavior, and myriad of management options. Hematol Oncol Chil North Am. 2013;27:989–1005.CrossRef
6.
go back to reference Reitamo JJ, Häyry P, Nykyri E, Saxén E. The desmoid tumor. I. Incidence, sex, age, and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77(6):665–73.PubMed Reitamo JJ, Häyry P, Nykyri E, Saxén E. The desmoid tumor. I. Incidence, sex, age, and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77(6):665–73.PubMed
7.
go back to reference Häyry P, Reitamo JJ, Tötterman S, Hopfner-Hallikainen D, Sivula A. The desmoid tumor. II. Analysis of factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol. 1982;77(6):674–80.PubMed Häyry P, Reitamo JJ, Tötterman S, Hopfner-Hallikainen D, Sivula A. The desmoid tumor. II. Analysis of factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol. 1982;77(6):674–80.PubMed
8.
go back to reference Häyry P, Reitamo JJ, Vihko R, et al. The desmoid tumor. III. A biochemical and genetic analysis. Am J Clin Pathol. 1982;77(6):681–5.PubMed Häyry P, Reitamo JJ, Vihko R, et al. The desmoid tumor. III. A biochemical and genetic analysis. Am J Clin Pathol. 1982;77(6):681–5.PubMed
9.
go back to reference Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, Dekkers OM, Hogendoorn PC, Vasen HF. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011;129(1):256–61.PubMedCrossRef Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, Dekkers OM, Hogendoorn PC, Vasen HF. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011;129(1):256–61.PubMedCrossRef
10.
go back to reference Robanus-Maandag E, Bosch C, Amini-Nik S, et al. Familial adenomatous polyposis-associated desmoids display significantly more genetic changes than sporadic desmoids. PLoS One. 2011;6(9):e24354.PubMedCentralPubMedCrossRef Robanus-Maandag E, Bosch C, Amini-Nik S, et al. Familial adenomatous polyposis-associated desmoids display significantly more genetic changes than sporadic desmoids. PLoS One. 2011;6(9):e24354.PubMedCentralPubMedCrossRef
11.
go back to reference Durno C, Monga N, Bapat B, Berk T, Cohen Z, Gallinger S. Does early colectomy increase desmoid risk in familial adenomatous polyposis? Clin Gastroenterol Hepatol. 2007;5(10):1190–4.PubMedCrossRef Durno C, Monga N, Bapat B, Berk T, Cohen Z, Gallinger S. Does early colectomy increase desmoid risk in familial adenomatous polyposis? Clin Gastroenterol Hepatol. 2007;5(10):1190–4.PubMedCrossRef
12.
go back to reference Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;71:441–7.PubMedCrossRef Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;71:441–7.PubMedCrossRef
13.
go back to reference Ballo MT, Zagers GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158–67.PubMed Ballo MT, Zagers GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158–67.PubMed
14.
go back to reference Baumert BG, Spahr MO, Van Hochsetter A, et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the rare cancer network. Radiat Oncol. 2007;2:12.PubMedCentralPubMedCrossRef Baumert BG, Spahr MO, Van Hochsetter A, et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the rare cancer network. Radiat Oncol. 2007;2:12.PubMedCentralPubMedCrossRef
15.
go back to reference van Broekhoven DLM, Verhoef C, Elias SG, et al. Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg. 2013;100(9):1214–1219.PubMedCrossRef van Broekhoven DLM, Verhoef C, Elias SG, et al. Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg. 2013;100(9):1214–1219.PubMedCrossRef
17.
go back to reference ESMO Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:92–9.CrossRef ESMO Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:92–9.CrossRef
18.
go back to reference Keus RB, Nout RA, Blay JY, et al. Results of a phase II pilot study for moderate dose radiotherapy for inoperable desmoid-type fibromatosis: an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol. 2013;24(10):2672–6.PubMedCrossRef Keus RB, Nout RA, Blay JY, et al. Results of a phase II pilot study for moderate dose radiotherapy for inoperable desmoid-type fibromatosis: an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol. 2013;24(10):2672–6.PubMedCrossRef
19.
go back to reference van Broekhoven DLM, Deroose JP, Bonvalot S, et al. Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis. Br J Surg. 2014;101(13):1674–80.PubMedCrossRef van Broekhoven DLM, Deroose JP, Bonvalot S, et al. Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis. Br J Surg. 2014;101(13):1674–80.PubMedCrossRef
20.
go back to reference Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23:182–6.PubMedCrossRef Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23:182–6.PubMedCrossRef
21.
go back to reference Bocale D, Rotelli MT, Cavallini A, et al. Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis. 2011;13(12):e388–95.PubMedCrossRef Bocale D, Rotelli MT, Cavallini A, et al. Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis. 2011;13(12):e388–95.PubMedCrossRef
22.
go back to reference Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22(2):452–7.PubMedCrossRef Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22(2):452–7.PubMedCrossRef
23.
go back to reference Casparie M, Tiebosch ATMG, Burger G, Blauwgeers H, Pol A, van de Krieken JHJM, van Meijer GA. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histiopathology and cytopathology data network and archive. Cell Oncol. 2007;29:19–24.PubMed Casparie M, Tiebosch ATMG, Burger G, Blauwgeers H, Pol A, van de Krieken JHJM, van Meijer GA. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histiopathology and cytopathology data network and archive. Cell Oncol. 2007;29:19–24.PubMed
25.
go back to reference Fletcher CDM, Unni KK, Mertens F editors. Tumours of soft tissue and bone: pathology and genetics. World Health Organization classification of tumours, 3rd edn. Lyon: IARC Press; 2002. Fletcher CDM, Unni KK, Mertens F editors. Tumours of soft tissue and bone: pathology and genetics. World Health Organization classification of tumours, 3rd edn. Lyon: IARC Press; 2002.
27.
go back to reference Montgomery E, Torbenson MS, Kaushal M, Fisher C, Abraham SC. Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol. 2002;26(10):1296–301.PubMedCrossRef Montgomery E, Torbenson MS, Kaushal M, Fisher C, Abraham SC. Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol. 2002;26(10):1296–301.PubMedCrossRef
28.
go back to reference Cheon SS, Cheah AY, Turley S, et al. Beta-catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA. 2002;99(10):6973–8.PubMedCentralPubMedCrossRef Cheon SS, Cheah AY, Turley S, et al. Beta-catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA. 2002;99(10):6973–8.PubMedCentralPubMedCrossRef
29.
go back to reference Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al. Nuclear beta-catenin expression distinguished deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 2005;29(5):653–9.PubMedCrossRef Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al. Nuclear beta-catenin expression distinguished deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 2005;29(5):653–9.PubMedCrossRef
30.
go back to reference Gronchi A, Colombo C, Le Péchoux C, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplams—a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014;25(3):578–83.PubMedCentralPubMedCrossRef Gronchi A, Colombo C, Le Péchoux C, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplams—a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014;25(3):578–83.PubMedCentralPubMedCrossRef
31.
go back to reference Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16(9):2587–93.PubMedCrossRef Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16(9):2587–93.PubMedCrossRef
32.
go back to reference Kasper B. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise—a European Organisation for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) and Sarcoma Patients Euronet (SPAEN) Initiative. Eur J Cancer. 2015;51(2):127–36.PubMedCrossRef Kasper B. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise—a European Organisation for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) and Sarcoma Patients Euronet (SPAEN) Initiative. Eur J Cancer. 2015;51(2):127–36.PubMedCrossRef
Metadata
Title
Time Trends in the Incidence and Treatment of Extra-Abdominal and Abdominal Aggressive Fibromatosis: A Population-Based Study
Authors
Danique L. M. van Broekhoven, MD
Dirk J. Grünhagen, MD, PhD
Michael A. den Bakker, MD, PhD
Thijs van Dalen, MD, PhD
Cornelis Verhoef, MD, PhD
Publication date
01-09-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 9/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4632-y

Other articles of this Issue 9/2015

Annals of Surgical Oncology 9/2015 Go to the issue